Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cullinan Oncology, Inc.

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Tickers CGEM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.